Linked Life Data

19710552

Source:http://linkedlifedata.com/resource/pubmed/id/19710552

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2009-8-27
pubmed:abstractText
Though alefacept and efalizumab do not have robust development for treating inflammatory disorders other than psoriasis, they provided important therapeutic options for patients with chronic plaque psoriasis. Alefacept is administered in 12-week cycles and requires routine monitoring of CD4 lymphocyte counts as apoptosis of memory T cells is a hallmark of its mechanisms of action. In contrast, it is recommended to conduct monthly complete blood counts for patients on efalizumab during the first few months of therapy; efalizumab is intended for continuous long-term therapy. Alefacept works extremely well for a smaller cohort of patients. We cannot yet predetermine those who will respond through many cycles of alefacept. Efalizumab works extremely well for approximately 40% of subjects, and possibly more when retreatment options are considered. Most important for patients on either therapy is appropriate intermittent clinical evaluations to ensure stable, safe, and effective therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1421-5721
pubmed:author
pubmed:copyrightInfo
Copyright (c) 038\ S. Karger AG, Basel.
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
95-106
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Monitoring patients treated with efalizumab or alefacept.
pubmed:affiliation
Probity Medical Research, Waterloo, ON, Canada. kapapp@probitymedical.com
pubmed:publicationType
Journal Article, Review